Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd Past Earnings Performance
Past criteria checks 0/6
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd's earnings have been declining at an average annual rate of -2.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 6.9% per year. Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd's return on equity is 4.8%, and it has net margins of 17.5%.
Key information
-2.6%
Earnings growth rate
-11.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -6.9% |
| Return on equity | 4.8% |
| Net Margin | 17.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd's (SZSE:301130) Weak Earnings Might Be Worse Than They Appear
Nov 02
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Strong Profits May Be Masking Some Underlying Issues
Apr 29Recent updates
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd's (SZSE:301130) Weak Earnings Might Be Worse Than They Appear
Nov 02Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Is Increasing Its Dividend To CN¥0.26
Jun 07Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Strong Profits May Be Masking Some Underlying Issues
Apr 29Revenue & Expenses Breakdown
How Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 248 | 43 | 141 | 13 |
| 30 Jun 24 | 240 | 45 | 139 | 13 |
| 31 Mar 24 | 237 | 55 | 141 | 11 |
| 31 Dec 23 | 225 | 51 | 142 | 9 |
| 30 Sep 23 | 242 | 50 | 147 | 13 |
| 30 Jun 23 | 253 | 50 | 156 | 12 |
| 31 Mar 23 | 258 | 42 | 157 | 12 |
| 01 Jan 23 | 255 | 41 | 154 | 12 |
| 30 Sep 22 | 263 | 50 | 159 | 7 |
| 30 Jun 22 | 266 | 50 | 160 | 8 |
| 31 Mar 22 | 271 | 48 | 162 | 11 |
| 01 Jan 22 | 286 | 52 | 169 | 13 |
| 30 Sep 21 | 289 | 49 | 174 | 11 |
| 30 Jun 21 | 300 | 52 | 181 | 10 |
| 31 Mar 21 | 293 | 51 | 181 | 7 |
| 31 Dec 20 | 286 | 50 | 181 | 4 |
| 31 Dec 19 | 325 | 55 | 195 | 17 |
| 31 Dec 18 | 280 | 41 | 171 | 21 |
| 31 Dec 17 | 274 | 46 | 169 | 12 |
Quality Earnings: 301130 has a high level of non-cash earnings.
Growing Profit Margin: 301130's current net profit margins (17.5%) are lower than last year (20.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301130's earnings have declined by 2.6% per year over the past 5 years.
Accelerating Growth: 301130's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301130 had negative earnings growth (-13.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 301130's Return on Equity (4.8%) is considered low.